Papillary renal cell carcinoma in contrast-enhanced ultrasound (CEUS) - A diagnostic performance study.


Journal

Clinical hemorheology and microcirculation
ISSN: 1875-8622
Titre abrégé: Clin Hemorheol Microcirc
Pays: Netherlands
ID NLM: 9709206

Informations de publication

Date de publication:
2019
Historique:
pubmed: 20 12 2018
medline: 4 6 2019
entrez: 20 12 2018
Statut: ppublish

Résumé

Renal cell carcinomas (RCC) represent a heterogeneous group of hypo- and hypervascularized malignancies. Using contrast-enhanced ultrasound (CEUS) specific imaging features of clear cell (ccRCC), papillary (pRCC) and chromophobe RCC (chRCC) subtypes have been demonstrated. However, some RCCs show atypical imaging features making it difficult to distinguish between the subtypes. This study was performed to evaluate the observed enhancement features of pRCC in CEUS and to assess the sensitivity in the diagnosis of suspected renal malignancies in a 10 year retrospective analysis at our institution. The study population consisted of 60 patients with histologically confirmed pRCC. All patients underwent CEUS imaging between 2005 and 2015 as part of their diagnostic workup. In 45 out of 60 (75%) cases the examined pRCC showed typical hypoenhancement and wash-out. 15 out of 60 (25%) pRCC showed atypical enhancement features; in 14 cases the contrast enhancement indicated a ccRCC. 1 complex cyst was falsely reported as IIF lesion. 59 out of 60 malignancies were reported as malignant using CEUS resulting in a sensitivity of 98.4%. CEUS is an eligible imaging technique to visualize the contrast enhancement features of pRCC. However, up to 25% of pRCCs show an atypical enhancement pattern making it difficult to distinguish it from other renal lesions.

Sections du résumé

BACKGROUND BACKGROUND
Renal cell carcinomas (RCC) represent a heterogeneous group of hypo- and hypervascularized malignancies. Using contrast-enhanced ultrasound (CEUS) specific imaging features of clear cell (ccRCC), papillary (pRCC) and chromophobe RCC (chRCC) subtypes have been demonstrated. However, some RCCs show atypical imaging features making it difficult to distinguish between the subtypes.
OBJECTIVE OBJECTIVE
This study was performed to evaluate the observed enhancement features of pRCC in CEUS and to assess the sensitivity in the diagnosis of suspected renal malignancies in a 10 year retrospective analysis at our institution.
METHODS METHODS
The study population consisted of 60 patients with histologically confirmed pRCC. All patients underwent CEUS imaging between 2005 and 2015 as part of their diagnostic workup.
RESULTS RESULTS
In 45 out of 60 (75%) cases the examined pRCC showed typical hypoenhancement and wash-out. 15 out of 60 (25%) pRCC showed atypical enhancement features; in 14 cases the contrast enhancement indicated a ccRCC. 1 complex cyst was falsely reported as IIF lesion. 59 out of 60 malignancies were reported as malignant using CEUS resulting in a sensitivity of 98.4%.
CONCLUSIONS CONCLUSIONS
CEUS is an eligible imaging technique to visualize the contrast enhancement features of pRCC. However, up to 25% of pRCCs show an atypical enhancement pattern making it difficult to distinguish it from other renal lesions.

Identifiants

pubmed: 30562896
pii: CH189406
doi: 10.3233/CH-189406
doi:

Substances chimiques

Contrast Media 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

159-164

Auteurs

K Mueller-Peltzer (K)

Department of Radiology, Ludwig-Maximilians-University Munich, Grosshadern Campus, Munich, Germany.

G Negrao de Figueiredo (G)

Department of Radiology, Ludwig-Maximilians-University Munich, Grosshadern Campus, Munich, Germany.

T Graf (T)

Department of Radiology, Ludwig-Maximilians-University Munich, Grosshadern Campus, Munich, Germany.

J Rübenthaler (J)

Department of Radiology, Ludwig-Maximilians-University Munich, Grosshadern Campus, Munich, Germany.

D-A Clevert (DA)

Department of Radiology, Ludwig-Maximilians-University Munich, Grosshadern Campus, Munich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH